Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jul 1;116(7):1080-1086.
doi: 10.1093/jnci/djae038.

Use of cancer-directed therapy at the end of life among adolescents and young adults

Jennifer W Mack  1   2 , Colin Cernik  1 , Lanfang Xu  3 , Cecile A Laurent  4 , Lauren Fisher  1 , Nancy Cannizzaro  5 , Julie Munneke  4 , Robert M Cooper  6 , Joshua R Lakin  7 , Corey M Schwartz  8 , Mallory Casperson  9 , Andrea Altschuler  4 , Lori Wiener  10 , Lawrence H Kushi  4 , Chun R Chao  5 , Hajime Uno  1
Affiliations

Use of cancer-directed therapy at the end of life among adolescents and young adults

Jennifer W Mack et al. J Natl Cancer Inst. .

Abstract

Background: Adolescents and young adults frequently receive chemotherapy near death. We know less about the use of targeted agents and immunotherapy or trends over time.

Methods: We conducted a retrospective cohort study of 1836 adolescents and young adults with cancer who died between 2009 and 2019 after receiving care at 1 of 3 sites (Dana-Farber Cancer Institute, Kaiser Permanente Northern California, and Kaiser Permanente Southern California). We reviewed electronic health data and medical records to examine use of cancer-directed therapy in the last 90 days of life, including chemotherapy, targeted therapy, immunotherapy, and investigational drugs.

Results: Over the study period, 35% of adolescents and young adults received chemotherapy in the last 90 days of life; 24% received targeted therapy, 7% immunotherapy, and 5% investigational drugs. Additionally, 56% received at least 1 form of systemic cancer-directed therapy in the last 90 days of life. After adjustment for patient sex, race, ethnicity, age, site of care, diagnosis, and years from diagnosis to death, the proportion of adolescents and young adults receiving targeted therapy (odds ratio [OR] = 1.05 per year of death, 95% confidence interval [CI] = 1.02 to 1.10; P = .006), immunotherapy (OR = 1.27, 95% CI = 1.18 to 1.38; P < .0001), and any cancer-directed therapy (OR = 1.04, 95% CI = 1.01 to 1.08; P = .01) in the last 90 days of life increased over time.

Conclusions: More than half of adolescents and young adults receive cancer therapy in the last 90 days of life, and use of novel agents such as targeted therapy and immunotherapy is increasing over time. Although some adolescents and young adults may wish to continue cancer therapy while living with advanced disease, efforts are needed to ensure that use of cancer-directed therapy meets preferences of adolescents and young adults approaching death.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to disclose.

Figures

Figure 1.
Figure 1.
Trends in the use of cancer-directed therapy in the last 90 days of life, 2009-2019.
Figure 2.
Figure 2.
Trends in the use of chemotherapy in the last 14 days of life, 2009-2019.
See this image and copyright information in PMC

References

    1. Wright AA, Zhang B, Keating NL, Weeks JC, Prigerson HG.. Associations between palliative chemotherapy and adult cancer patients’ end of life care and place of death: prospective cohort study. BMJ. 2014;348:g1219. doi:10.1136/bmj.g1219. - DOI - PMC - PubMed
    1. Hui D, Didwaniya N, Vidal M, et al.Quality of end-of-life care in patients with hematologic malignancies: a retrospective cohort study. Cancer. 2014;120(10):1572-1578. doi:10.1002/cncr.28614. - DOI - PMC - PubMed
    1. Prigerson HG, Bao Y, Shah MA, et al.Chemotherapy use, performance status, and quality of life at the end of life. JAMA Oncol. 2015;1(6):778-784. doi:10.1001/jamaoncol.2015.2378. - DOI - PMC - PubMed
    1. Peppercorn JM, Smith TJ, Helft PR, et al.; American Society of Clinical Oncology American society of clinical oncology statement: toward individualized care for patients with advanced cancer. J Clin Oncol. 2011;29(6):755-760. doi:10.1200/JCO.2010.33.1744 - DOI - PubMed
    1. Siegel RL, Miller KD, Fuchs HE, Jemal A.. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7-33. doi:10.3322/caac.21708. - DOI - PubMed

Substances